Back to top
more

Onconova Therapeutics, Inc. (ONTX)

(Delayed Data from NSDQ)

$4.07 USD

4.07
50,029

0.00 (0.00%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.16 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Stevanato Group (STVN) Q3 Earnings Meet Estimates

by Zacks Equity Research

Stevanato (STVN) delivered earnings and revenue surprises of 0% and 3.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Durect (DRRX) delivered earnings and revenue surprises of -2.22% and 27.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -3.70% and 6.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 130% and 18.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Onconova Therapeutics, Inc. (ONTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -23.81% and 5%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug

by Zacks Equity Research

The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.

Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

by Zacks Equity Research

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -40% and 6.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of -100% and 20.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.

Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study

by Zacks Equity Research

Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.

Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.

Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Onconova (ONTX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Onconova (ONTX) stock based on the movements in the options market lately.

Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer

by Zacks Equity Research

Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control potential.

Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 3.57% and 35.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Onconova Therapeutics, Inc. (ONTX) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Onconova Therapeutics, Inc. (ONTX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Onconova Therapeutics, Inc. (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) beat estimates for both earnings and revenues in the first quarter of 2021.

Jazz Pharma's Xywav Succeeds in Idiopathic Hypersomnia Study

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares rise.